Myeloproliferative Neoplasms News

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 10-13 in New Orleans.

The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and rearrangement of fibroblast growth factor receptor 1, according to a press release from the agent’s manufacturer.

Firefighters and EMS providers with low levels of serum IgE who responded to the attack on the World Trade Center on and after Sept. 11, 2001, had significantly higher odds for developing a hematologic malignancy, a recent study reported.

Aaron T. Gerds, MD, MS, spoke with Healio about the randomized phase 3 MOMENTUM study.

Active systemic cancer treatment did not appear associated with increased mortality among patients with cancer and COVID-19, according to study results published in JAMA Network Open.

CHICAGO — David Andrew Sallman, MD, myeloid section head at Moffitt Cancer Center, talked about two presentations on molecular targeted therapy from the ASCO Annual Meeting.

CHICAGO — In a video interview, Aaron Thomas Gerds, MD, MS, discussed the efficacy and safety of momelotinib in a subset of patients with thrombocytopenic myelofibrosis from the MOMENTUM study, which was presented at ASCO Annual Meeting.

CHICAGO — Aaron Thomas Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, spoke with Healio about topline results from the MOMENTUM study presented at ASCO Annual Meeting.

CHICAGO — In a video interview, David Andrew Sallman, MD, discussed results from the final analysis of magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes presented at ASCO Annual Meeting.

CHICAGO — In a video interview, Healio spoke with David Andrew Sallman, MD, myeloid section head at Moffitt Cancer Center, about using targeted therapy in patients with myelodysplastic syndrome at ASCO Annual Meeting.